Voyager Therapeutics (VYGR) Preferred Stock Liabilities (2014 - 2016)

Voyager Therapeutics has disclosed Preferred Stock Liabilities across 3 years of filings, most recently posting $36.1 million for Q4 2016.

• Preferred Stock Liabilities for Q4 2016 came in at $36.1 million, changed 0.13% year-over-year; the trailing twelve-month figure through Dec 2016 was $36.1 million (changed 0.13% YoY), and the FY2016 annual result was $36.1 million, changed 0.13% from the prior year.
• Preferred Stock Liabilities came in at $36.1 million for Q4 2016 at Voyager Therapeutics, roughly flat from $36.1 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $36.1 million in Q4 2016 to a low of $22.0 million in Q4 2014.
• The 3-year median for Preferred Stock Liabilities is $36.1 million (2015), against an average of $32.5 million.
• Across the five-year window, Preferred Stock Liabilities surged 64.04% in 2015 and grew 0.13% in 2016, its largest moves.
• Voyager Therapeutics' Preferred Stock Liabilities stood at $22.0 million in 2014, then surged by 64.04% to $36.1 million in 2015, then climbed by 0.13% to $36.1 million in 2016.
• The last three Preferred Stock Liabilities figures came in at $36.1 million (Q4 2016), $36.1 million (Q4 2015), and $36.1 million (Q3 2015), per Business Quant data.